Yayın:
The effects of atorvastatin on oxidative stress in L-NAME-treated rats

dc.contributor.authorSozer, Volkan
dc.contributor.authorUzun, Hafize
dc.contributor.authorGelisgen, Remise
dc.contributor.authorKaya, Mehmet
dc.contributor.authorKalayci, Rivase
dc.contributor.authorTabak, Omur
dc.contributor.authorArican, Nadir
dc.contributor.authorKonukoglu, Dildar
dc.date.accessioned2026-06-27T13:23:37Z
dc.date.issued2013
dc.description.abstractObjectives. Current evidence suggests that the beneficial vascular effects of statins are not limited to the statins' lipid-lowering properties; these drugs can also improve vascular endothelial cell function. N omega-nitro-l-arginine methyl ester (L-NAME) is a potent synthetic nitric oxide inhibitor, and long-term oral L-NAME treatment is used to induce vascular lesions in experimental animal models. Methods. We determined the effects of statins on protein carbonyl (PCO), lipid hydroperoxides (LHP), oxidized low-density lipoproteins (ox-LDL) and antioxidants such as paraoxonase 1 (PON1) and total thiols (T-SH) in long-term L-NAME-treated rats. Adult male Wistar rats were divided into three groups, namely, control, L-NAME-treated (1 mg/mL in drinking water for three weeks), and atorvastatin plus L-NAME-treated (4 mg/kg/day atorvastatin for 1 week during the third week of L-NAME treatment) groups. Results. In the L-NAME group, the ox-LDL, LHP and PCO were higher and the PON1 and T-SH were lower than the concentrations observed for the controls. When compared with the L-NAME group, the L-NAME plus atorvastatin group had significantly lower ox-LDL and LHP and higher PON1 activities. Additionally, the elevated total cholesterol (TC) and low-density lipoprotein-C (LDL-C) in the L-NAME group were decreased by atorvastatin administration. TC and LDL-C were positively correlated with ox-LDL and LHP and negatively correlated with PON1 in all groups. High-density lipoprotein-C (HDL-C) was negatively correlated with ox-LDL. Conclusion. PON1 prevents LDL oxidation and inactivates LDL-derived oxidized phospholipids; its activity showed a pronounced decrease in the L-NAME treatment group and was increased in the atorvastatin group. Based on our findings, we concluded that the atorvastatin had HDL-related antioxidant activity as well as lipid-lowering properties.en
dc.description.urihttps://doi.org/10.3109/00365513.2013.828241
dc.identifier.doi10.3109/00365513.2013.828241
dc.identifier.eissn1502-7686
dc.identifier.endpage597
dc.identifier.issn0036-5513
dc.identifier.issue7
dc.identifier.pubmed24024670
dc.identifier.startpage591
dc.identifier.urihttps://hdl.handle.net/20.500.14981/52570
dc.identifier.volume73
dc.identifier.wos000325493500009
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofSCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
dc.subjectOxidative stress
dc.subjectL-NAME
dc.subjectstatin
dc.subjectox-LDL
dc.subjectparaoxonase
dc.subjectcholesterol
dc.subjectCOA REDUCTASE INHIBITORS
dc.subjectNITRIC-OXIDE
dc.subjectL-ARGININE
dc.subjectPARAOXONASE ACTIVITY
dc.subjectPROTEIN OXIDATION
dc.subjectANGIOTENSIN-II
dc.subjectREDOX STATE
dc.subjectANTIOXIDANT
dc.subjectHYPERTENSION
dc.subjectATHEROSCLEROSIS
dc.subjectMedical Laboratory Technology
dc.subjectResearch & Experimental Medicine
dc.titleThe effects of atorvastatin on oxidative stress in L-NAME-treated rats
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar